- Stocks
- Pharma & Healthcare
- Biofil Chemicals & Pharmaceuticals
Biofil Chemicals & Pharmaceuticals share price
NSE: BIOFILCHEMPharma & HealthcareDrug Manufacturers - Specialty & Generic
Biofil Chemicals & Pharmaceuticals at a glance
Biofil Chemicals & Pharmaceuticals (NSE: BIOFILCHEM) closed at ₹30.00 on 22 Oct 2026, up 2.15% on the day. With a market capitalisation of ₹49 Cr, it ranks 3083rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 17.5× trailing earnings, against a return on equity of 3.0% in FY25. Over the past year the share price has fallen 27.3%. Its 52-week range is ₹25.60 (30 Mar 2026) to ₹46.34 (3 Feb 2026); the last close is 35.3% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹8 Cr (−9.3% year on year) and net profit ₹0 Cr (+5.0%), on a standalone basis. Promoters held 46.79% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹49 CrRank 3083 on NSE
- P/E (trailing)
- 17.5×
- Price to book
- 3.56×FY25
- EPS (TTM)
- ₹1.71to Q4 FY26
- ROE
- 3.0%FY25
- ROCE
- 4.0%FY25
- Debt to equity
- 0.03FY25
- Net profit margin
- 1.7%FY25
- Book value / share
- ₹11.54FY25
- 52-week high
- ₹46.343 Feb 2026
- 52-week low
- ₹25.6030 Mar 2026
- 1-year return
- −27.3%
- RSI (14-day)
- 44.2
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +2.15% | −0.7% | −8.0% | −10.5% | −27.3% |
Biofil Chemicals & Pharmaceuticals quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹8 Cr | ₹2 Cr | ₹14 Cr | ₹8 Cr | ₹6 Cr | ₹14 Cr | ₹1 Cr | ₹8 Cr |
| Revenue YoY | +247.3% | −86.1% | +182.3% | −45.1% | −23.8% | +461.8% | −93.9% | −9.3% |
| Net profit | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹2 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Net profit YoY | −29.2% | −83.3% | +77.8% | −20.0% | +1,317.6% | +300.0% | −50.0% | +5.0% |
| Net margin | 2.0% | 0.8% | 1.1% | 2.4% | 37.5% | 0.6% | 9.3% | 2.8% |
| EPS | ₹0.10 | ₹0.01 | ₹0.10 | ₹0.12 | ₹1.48 | ₹0.05 | ₹0.05 | ₹0.13 |
Biofil Chemicals & Pharmaceuticals financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹30 Cr | ₹36 Cr | ₹22 Cr | ₹30 Cr | ₹40 Cr | ₹33 Cr |
| Operating profit | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Net profit | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| EPS (₹) | ₹0.74 | ₹0.76 | ₹0.44 | ₹0.34 | ₹0.44 | ₹0.34 |
| Cash from operations | ₹1 Cr | ₹1 Cr | −₹0 Cr | −₹0 Cr | ₹2 Cr | −₹2 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹15 Cr | ₹16 Cr | ₹17 Cr | ₹17 Cr | ₹18 Cr | ₹19 Cr |
Biofil Chemicals & Pharmaceuticals shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 46.82% | 46.82% | 46.79% | 46.79% | 46.79% | 46.79% |
| Domestic institutions | 0.08% | 0.08% | 0.08% | 0.08% | 0.08% | 0.08% |
| Non-institutions | 53.10% | 53.10% | 53.13% | 53.13% | 53.13% | 53.13% |
Biofil Chemicals & Pharmaceuticals vs peers
The listed Pharma & Healthcare companies nearest to Biofil Chemicals & Pharmaceuticals by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| VIVIMEDLABVivimed Labs | ₹6.21 | −1.90% | −45.8% | ₹51 Cr | — | — |
| SHREEPACShree Pacetroni | — | — | — | ₹50 Cr | — | — |
| BIOFILCHEMBiofil Chemicals & Pharmaceuticals | ₹30.00 | +2.15% | −27.3% | ₹49 Cr | 17.5 | — |
| SHANMUGAShanmuga Hospit | — | — | — | ₹48 Cr | — | — |
| MANGALAMMangalam Drugs And Organics | ₹29.66 | −3.07% | −58.5% | ₹47 Cr | — | — |
| AMKAYAmkay Products | — | — | — | ₹46 Cr | — | — |
| SHELTERShelter Pharma | — | — | — | ₹46 Cr | — | — |
Ask anything about Biofil Chemicals & Pharmaceuticals
Pivot answers on the live chart with evidence you can check, and tests strategies against BIOFILCHEM's own history. Try: “Why has BIOFILCHEM moved over the last three months?” · “Backtest a 50-day moving-average crossover on BIOFILCHEM over five years” · “Compare BIOFILCHEM with VIVIMEDLAB on margins and valuation”
Frequently asked questions about Biofil Chemicals & Pharmaceuticals
What is the share price of Biofil Chemicals & Pharmaceuticals today?
Biofil Chemicals & Pharmaceuticals (NSE: BIOFILCHEM) last closed at ₹30.00 on 22 Oct 2026. Its 52-week high is ₹46.34 and its 52-week low is ₹25.60.
What is the market cap of Biofil Chemicals & Pharmaceuticals?
Biofil Chemicals & Pharmaceuticals' market capitalisation is ₹49 Cr (₹49 Cr) at the 22 Oct 2026 close, ranking 3083rd among the NSE companies Pivot tracks.
What is the P/E ratio of Biofil Chemicals & Pharmaceuticals?
Biofil Chemicals & Pharmaceuticals trades at a trailing P/E of 17.5.
What is the ROE and ROCE of Biofil Chemicals & Pharmaceuticals?
Return on equity was 3.0% in FY25 and return on capital employed was 4.0% in FY25 (standalone figures).
Is Biofil Chemicals & Pharmaceuticals a debt-free company?
Biofil Chemicals & Pharmaceuticals is close to debt-free: its debt-to-equity ratio was 0.03 in FY25.
What were Biofil Chemicals & Pharmaceuticals' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Biofil Chemicals & Pharmaceuticals reported revenue of ₹8 Cr, −9.3% year on year, and net profit of ₹0 Cr, +5.0% year on year.
How has Biofil Chemicals & Pharmaceuticals stock performed over the last year?
Biofil Chemicals & Pharmaceuticals' share price has fallen 27.3% over the past year, −10.5% over three months and −8.0% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Biofil Chemicals & Pharmaceuticals?
As of 30 Jun 2026: promoters 46.79%, domestic institutions 0.08%, non-institutions 53.13%.
Who are Biofil Chemicals & Pharmaceuticals' competitors?
The listed Pharma & Healthcare companies closest to Biofil Chemicals & Pharmaceuticals by market cap are Vivimed Labs, Shree Pacetroni, Shanmuga Hospit, Mangalam Drugs And Organics, Amkay Products and Shelter Pharma.
Is Biofil Chemicals & Pharmaceuticals a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Biofil Chemicals & Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BIOFILCHEM against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with B · all NSE stocks · this page as text